<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of ovarian hyperstimulation syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of ovarian hyperstimulation syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of ovarian hyperstimulation syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cristiano E Busso, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sérgio Reis Soares, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antonio Pellicer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H16016150"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of controlled ovarian hyperstimulation (COH) for assisted reproduction. It is characterized by a broad spectrum of signs and symptoms that includes abdominal distention and discomfort, enlarged ovaries, ascites, and other complications of enhanced vascular permeability. The syndrome can be strictly defined as the shift of serum from the intravascular space to the third space, mainly to the abdominal cavity, in the context of enlarged ovaries due to follicular stimulation. In its very severe form, OHSS is a life-threatening condition.</p><p>The management of OHSS will be reviewed here. The pathogenesis, clinical manifestations, and prevention of OHSS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H16016168"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>OHSS is an iatrogenic and potentially life-threatening condition that affects young, healthy females [<a href="#rid1">1,2</a>]. In addition, there is an important economic burden associated with OHSS due to absence from work, bed rest, or hospitalization and intensive medical management of severe cases.</p><p>The pathophysiology of OHSS is not fully understood, but increased capillary permeability with the resulting loss of fluid into the third space is its main feature. In the susceptible patient, human chorionic gonadotropin (hCG) administration for final follicular maturation and triggering of ovulation is the pivotal stimulus for OHSS, leading to overexpression of vascular endothelial growth factor (VEGF) in the ovary, release of vasoactive-angiogenic substances, increased vascular permeability, loss of fluid to the third space, and full-blown OHSS (<a class="graphic graphic_algorithm graphicRef66510" href="/z/d/graphic/66510.html" rel="external">algorithm 1</a>).</p><p>There are two clinical forms of OHSS, both hCG related: the early-onset form (occurring on the first eight days after exogenous hCG administration) and the late-onset form (occurring nine or more days after hCG administration, related to pregnancy-induced hCG production) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome", section on 'Onset'</a>.)</p><p class="headingAnchor" id="H2924902367"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The keys to preventing OHSS are to identify the potential risk for the individual patient and to plan appropriate strategies to avoid its occurrence. The main steps include recognizing risk factors, using individualized ovarian stimulation regimens for assisted reproduction, modifying treatment when indicators for increasing OHSS risk develop, and using an alternative to standard-dose human chorionic gonadotropin (hCG) agonist for final oocyte maturation. The use of GnRH agonists for final oocyte maturation are associated with much lower risks of OHSS than hCG [<a href="#rid4">4</a>]. These strategies, as well as other interventions that are thought to be ineffective (eg, intravenous albumin), are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H16016610"><span class="h1">APPROACH TO MANAGEMENT</span><span class="headingEndMark"> — </span>The management of established OHSS should be conservative and directed at symptoms and/or signs of worsening; many females can be managed as outpatients. However, females with severe or critical OHSS require hospitalization (in some cases in the intensive care unit [ICU]). OHSS is a self-limited disease, although symptoms may be prolonged if pregnancy has occurred.</p><p>The general approach to managing the patient with OHSS is outlined in the algorithm (<a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>).</p><p>Our approach is similar to the American Society of Reproductive Medicine, the Royal College of Physicians of Ireland, and the Joint Society of Obstetricians and Gynecologists of Canada-Canadian Fertility and Andrology Society, all of whom have published clinical practice guidelines for OHSS [<a href="#rid5">5-7</a>].</p><p class="headingAnchor" id="H16016630"><span class="h2">Mild OHSS</span><span class="headingEndMark"> — </span>Most ovarian hyperstimulation syndrome (OHSS) cases are mild or moderate and can be managed on an outpatient basis (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a>). Normally, these cases are self-limited and can be managed conservatively, with a goal of relieving symptoms.</p><p>Mild OHSS is seen in many females undergoing ovarian stimulation for assisted reproduction. For mild OHSS, analgesics (<a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> rather than nonsteroidal anti-inflammatory drugs [NSAIDs]) and avoidance of heavy physical activity are usually enough. Patients should be instructed to call for any signs or symptoms of worsening (oliguria, abdominal distention, shortness of breath, or weight gain [a sign of fluid accumulation]) (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>).</p><p>Mild OHSS can progress to become moderate or severe, particularly if pregnancy has occurred. Therefore, females with mild disease should be observed for worsening abdominal pain, weight gain (&gt;1 kg/day), and increasing abdominal girth for at least two weeks or until menstrual bleeding occurs<em>. </em></p><p class="headingAnchor" id="H16016642"><span class="h2">Moderate OHSS</span><span class="headingEndMark"> — </span>For females with moderate ovarian hyperstimulation syndrome (OHSS), recommendations include (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Oral fluid intake of 1 to 2 liters per day. Diuretics are contraindicated because they can worsen decreased intravascular volume.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ambulate, but avoid other physical activity. Avoid sexual intercourse.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bed rest is sometimes necessary</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Daily weights, abdominal circumference measurements, and urinary output recordings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring for signs of progression is performed at the time of initial presentation and every 48 hours thereafter (or daily if worsening symptoms develop):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical examination</p><p class="bulletIndent2"><span class="glyph">•</span>Transvaginal ultrasound (TVUS)</p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory testing (complete blood count [CBC], electrolytes, creatinine, serum albumin, and liver enzymes)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Daily communication with patient:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Is hydration adequate?</p><p class="bulletIndent2"><span class="glyph">•</span>Document weight, abdominal circumference, and urine output</p><p class="bulletIndent2"><span class="glyph">•</span>Report any signs or symptoms of worsening</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant patients must be followed very closely as they are likely to worsen (or present with more severe symptoms) because of the rising levels of endogenous human chorionic gonadotropin (hCG) [<a href="#rid6">6</a>]. Pregnant patients with severe OHSS take longer to recover than nonpregnant patients (who typically experience resolution of symptoms within 10 to 14 days).</p><p></p><p class="headingAnchor" id="H16016702"><span class="h3">Ascites/culdocentesis</span><span class="headingEndMark"> — </span>Although transabdominal paracentesis is reported to be successful [<a href="#rid8">8</a>], most in vitro fertilization (IVF) centers are more experienced with transvaginal aspiration of the ascitic fluid from the cul-de-sac, guided by TVUS. Ultrasound-guided culdocentesis is often performed (even on an outpatient basis) in females with tense ascites, orthopnea, rapid increase of abdominal fluid, or any other sign that may indicate progression of illness [<a href="#rid7">7</a>]. Removal of ascitic fluid provides symptomatic relief; females without other complications can then continue to be monitored as outpatients. </p><p>The volume of fluid to be removed is not well established, but after aspiration of 500 mL of ascitic fluid, patients typically report resolution of abdominal discomfort. In one report of 19 females with OHSS, after aspiration of 2000 mL of ascites, a reduction in intra-abdominal pressure and renal artery resistance was seen, followed by an increase in urine output [<a href="#rid9">9</a>]. Removal of more than 4 liters of fluid is not recommended. Blind paracentesis should not be done, because of the potential risk of bowel or vessel puncture.</p><p class="headingAnchor" id="H1272517165"><span class="h3">Dopamine agonists (DA)</span><span class="headingEndMark"> — </span>In females at high risk for OHSS undergoing ovarian stimulation, the rate of developing moderate and severe OHSS can be significantly reduced with <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">cabergoline</a> (0.5 mg/day orally), beginning on the day of hCG administration or oocyte retrieval. Less is known about the efficacy of DA for the treatment of OHSS once it is established. However, some small studies suggest it may diminish clinical symptoms and severity [<a href="#rid10">10-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H16016756"><span class="h2">Severe and critical OHSS</span></p><p class="headingAnchor" id="H96981920"><span class="h3">Hospitalization</span><span class="headingEndMark"> — </span>Hospitalization is mandatory in females with severe ovarian hyperstimulation syndrome (OHSS) and any of the following criteria: a hematocrit &gt;55 percent, leukocytes &gt;25,000/L, and creatinine &gt;1.6 mg/dL. Females with severe abdominal pain, intractable vomiting, severe oliguria/anuria, tense ascites, dyspnea or tachypnea, hypotension, dizziness or syncope, severe electrolyte imbalance, or abnormal liver function tests must also be hospitalized (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>).</p><p>We suggest that females be hospitalized in a facility with extensive OHSS experience. Inpatient care consists of supportive care, monitoring, and prevention and treatment of complications.</p><p>Medical treatment of severe hyperstimulation is directed at maintaining intravascular blood volume. Although isotonic crystalloid solutions (eg, normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, Ringer's lactate) are typically used for intravenous hydration in patients with severe OHSS, some clinicians use intravenous albumin in critically ill, volume-depleted patients. However, available evidence suggests that intravenous albumin provides no additional benefit when compared with crystalloid solutions. (See  <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults", section on 'Normal saline (crystalloid)'</a>.)</p><p>Simultaneous goals are correcting the disturbed fluid and electrolyte balance, relieving secondary complications of ascites and hydrothorax, and preventing thromboembolic phenomena. We suggest thromboprophylaxis in <strong>all</strong> hospitalized patients with OHSS. (See <a class="local">'Prophylaxis for thromboembolic events'</a> below.)</p><p>In addition to volume management and prophylaxis for thromboembolism, patients should also be monitored for signs of infection. Bacterial peritonitis has been described in occasional patients [<a href="#rid14">14</a>]; other potential sources of infection include indwelling catheters and procedures to drain pleural and ascitic fluid. If bacterial infection is suspected, we suggest broad-spectrum empiric antibiotic therapy while awaiting culture results. We typically use a third- or fourth-generation cephalosporin in combination with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid15">15</a>].</p><p>Critical OHSS cases should be managed in an intensive care unit (ICU) [<a href="#rid16">16</a>]. Routine ICU care will not be reviewed here. However, aspects of daily monitoring that are particularly important for females with OHSS include (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>) [<a href="#rid6">6,16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of fluid balance (daily or more often)</p><p class="bulletIndent1"><span class="glyph">●</span>Weights and measurement of abdominal circumference</p><p class="bulletIndent1"><span class="glyph">●</span>CBC</p><p class="bulletIndent1"><span class="glyph">●</span>Electrolytes, blood urea nitrogen (BUN), creatinine </p><p class="bulletIndent1"><span class="glyph">●</span>Serum hCG measurements (to determine if patient has conceived)</p><p class="bulletIndent1"><span class="glyph">●</span>Invasive monitoring of central venous pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic ultrasound as needed to evaluate ovarian size and ascites</p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph and echocardiogram when pleural or pericardial effusion is suspected (as often as needed)</p><p></p><p>The management of severe complications such as massive hydrothorax, pericardial effusion, arterial thrombosis, pulmonary embolism, sepsis, acute renal failure, acute respiratory distress syndrome (ARDS), and disseminated intravascular coagulation (DIC) are reviewed in their relevant topics. (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H1581329517"><span class="h3">Prophylaxis for thromboembolic events</span><span class="headingEndMark"> — </span>We suggest prophylaxis for thromboembolism in the following settings [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>All hospitalized patients with OHSS. (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females with OHSS being managed as outpatients with two to three additional risk factors (in addition to OHSS): age &gt;35 years, obesity, immobility, elevated hematocrit, personal or family history of thrombosis, thrombophilias, and pregnancy. For those in whom bed rest is suggested, an intermittent pneumatic compression device is typically recommended. (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'Intermittent pneumatic compression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We use prophylactic low molecular weight heparin, 20 mg subcutaneously every 12 hours, or heparin 5000 units subcutaneously every 12 hours [<a href="#rid5">5-7</a>].</p><p></p><p class="headingAnchor" id="H16016828"><span class="h3">Resolution and prognosis</span><span class="headingEndMark"> — </span>The pathophysiological process of OHSS is self-limited, and increased vascular permeability regresses spontaneously. Those who have not conceived recover over 10 to 14 days from the onset of initial symptoms. Third-space fluid begins to re-enter the intravascular space, hemoconcentration reverses, and natural diuresis ensues. </p><p>Clinical evidence of resolution includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Normalization of hematocrit</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive reduction of ascites on ultrasound</p><p class="bulletIndent1"><span class="glyph">●</span>Alleviation of clinical symptoms</p><p></p><p>If pregnancy occurs, resolution may take longer [<a href="#rid18">18</a>]. As described above, OHSS may worsen initially as hCG levels rise. Some studies have suggested that OHSS pregnancies are associated with a higher rate of miscarriage and later complications, such as gestational diabetes and pregnancy-associated hypertension [<a href="#rid19">19,20</a>]. However, in a retrospective chart review of females undergoing IVF, similar rates of gestational diabetes and preeclampsia were seen in those who did and did not develop OHSS [<a href="#rid21">21</a>].   </p><p class="headingAnchor" id="H2935076910"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117617.html" rel="external">"Society guideline links: Ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H16016874"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian hyperstimulation syndrome (OHSS)</strong> – OHSS is the most serious complication of controlled ovarian hyperstimulation (COH) for assisted reproduction. It is a broad spectrum of signs and symptoms that include abdominal distention and discomfort, enlarged ovaries, ascites, and other complications of enhanced vascular permeability. (See <a class="local">'Background'</a> above.)</p><p></p><p class="bulletIndent1">OHSS is a self-limited disease, although symptoms may be prolonged if pregnancy has occurred. Management should be conservative and directed at symptoms; many females can be managed as outpatients. However, females with severe or critical OHSS require hospitalization (in some cases to the intensive care unit [ICU]). (See <a class="local">'Background'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild OHSS </strong>–<strong> </strong>Females with mild OHSS (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a>) should receive outpatient management that includes analgesics (<a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>) and avoidance of heavy physical activity. Patients should be instructed to call for any signs or symptoms of worsening (oliguria, abdominal distention, shortness of breath, or weight gain [a sign of fluid accumulation]). Females should also avoid sexual intercourse (which could cause discomfort and increase the risk of ovarian rupture). (See <a class="local">'Mild OHSS'</a> above.)</p><p></p><p class="bulletIndent2">Mild OHSS can progress to moderate or severe OHSS, particularly if pregnancy has occurred. Therefore, females with mild disease should be observed for worsening abdominal pain, weight gain (&gt;1 kg/day), and increasing abdominal girth for at least two weeks or until menstrual bleeding occurs (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>). (See <a class="local">'Mild OHSS'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate OHSS </strong>–<strong> </strong>Females with moderate OHSS should receive outpatient management that includes avoidance of physical activity, oral hydration (1 to 2 liters per day), and a baseline transvaginal ultrasound (TVUS) and complete blood count (CBC) to look for ascites and hemoconcentration, respectively. In addition, daily communication with the patient is done to monitor daily weights and abdominal circumference and to report any worsening signs and symptoms (oliguria, abdominal distention, shortness of breath, weight increase). Other monitoring for signs of progression should be done every 48 hours (or daily if symptoms are worsening), including physical and ultrasound examinations and laboratory testing (CBC, electrolytes, creatinine, serum albumin, and liver enzymes) (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>). (See <a class="local">'Moderate OHSS'</a> above.)</p><p></p><p class="bulletIndent2">Pregnant patients must be followed very closely as they are likely to worsen (or present with more severe symptoms) because of the rising levels of endogenous human chorionic gonadotropin (hCG) [<a href="#rid6">6</a>]. Pregnant patients take longer to recover than nonpregnant patients (who typically experience resolution of symptoms within 10 to 14 days). (See <a class="local">'Moderate OHSS'</a> above.)</p><p></p><p class="bulletIndent2">Ultrasound-guided culdocentesis is often performed (even on an outpatient basis) in females with tense ascites, orthopnea, rapid increase of abdominal fluid, or any other sign that may indicate progression of illness. (See <a class="local">'Ascites/culdocentesis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe OHSS </strong>–<strong> </strong>Females with severe OHSS and any of the following criteria: a hematocrit &gt;45 percent, leukocytes &gt;25,000/L, and creatinine &gt;1.6 mg/dL should be hospitalized. Females with severe abdominal pain, intractable vomiting, severe oliguria/anuria, tense ascites, dyspnea or tachypnea, hypotension, dizziness or syncope, severe electrolyte imbalance, and abnormal liver function tests must also be hospitalized (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>). (See <a class="local">'Hospitalization'</a> above.)</p><p></p><p class="bulletIndent2">We suggest thromboembolism prophylaxis for all hospitalized patients with OHSS (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In addition, we suggest prophylaxis for those managed as outpatients with two to three additional risk factors (in addition to OHSS): age &gt;35 years, obesity, immobility, elevated hematocrit, personal or family history of thrombosis, thrombophilias, and pregnancy. (See <a class="local">'Prophylaxis for thromboembolic events'</a> above.)</p><p></p><p class="bulletIndent2">Medical treatment of severe hyperstimulation is directed at maintaining intravascular blood volume. Simultaneous goals are correcting the disturbed fluid and electrolyte balance, relieving secondary complications of ascites and hydrothorax, and preventing thromboembolic events (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef101703" href="/z/d/graphic/101703.html" rel="external">algorithm 2</a>). (See <a class="local">'Hospitalization'</a> above.)</p><p></p><p class="headingAnchor" id="H605633769"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Bruno Lunenfeld, MD and the late Vaclav Insler, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Golan A, Ron-el R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 44:430.</a></li><li><a class="nounderline abstract_t">Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:883.</a></li><li><a class="nounderline abstract_t">Lyons CA, Wheeler CA, Frishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9:792.</a></li><li><a class="nounderline abstract_t">Fernández-Sánchez M, Fatemi H, García-Velasco JA, et al. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach. Gynecol Endocrinol 2023; 39:2205952.</a></li><li class="breakAll">http://www.rcpi.ie/content/docs/000001/654_5_media.pdf (Accessed on May 11, 2015).</li><li><a class="nounderline abstract_t">Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008; 90:S188.</a></li><li><a class="nounderline abstract_t">Joint Society of Obstetricians and Gynaecologists of Canada-Canadian Fertility Andrology Society Clinical Practice Guidelines Committee, Reproductive Endocrinology and Infertility Committee of the SOGC, Executive and Council of the Society of Obstetricians, et al. The diagnosis and management of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can 2011; 33:1156.</a></li><li><a class="nounderline abstract_t">Levin I, Almog B, Avni A, et al. Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome. Fertil Steril 2002; 77:986.</a></li><li><a class="nounderline abstract_t">Maslovitz S, Jaffa A, Eytan O, et al. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynecol 2004; 104:321.</a></li><li><a class="nounderline abstract_t">Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005; 122:127.</a></li><li><a class="nounderline abstract_t">Rollene NL, Amols MH, Hudson SBA, Coddington CC. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 2009; 92:1169.e15.</a></li><li><a class="nounderline abstract_t">Tsunoda T, Shibahara H, Hirano Y, et al. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol 2003; 17:281.</a></li><li><a class="nounderline abstract_t">Tang H, Mourad S, Zhai SD, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2016; 11:CD008605.</a></li><li><a class="nounderline abstract_t">Rehman A, Ul-Ain Baloch N, Awais M. Severe ovarian hyperstimulation syndrome complicated by Stenotrophomonas maltophilia peritonitis: a case report and literature review. Intern Med 2015; 54:1149.</a></li><li><a class="nounderline abstract_t">Timmons D, Montrief T, Koyfman A, Long B. Ovarian hyperstimulation syndrome: A review for emergency clinicians. Am J Emerg Med 2019; 37:1577.</a></li><li class="breakAll">Busso CE, Garcia-Velasco JA, Gomez R, et al. Ovarian hyperstimulation syndrome. In: Infertility and assisted reproduction, Rizk B, Garcia-Velasco JA, Sallam HM, Makrigiannakis A (Eds), Cambridge University Press, Cambridge, UK 2008. p.243.</li><li><a class="nounderline abstract_t">Kasum M, Danolić D, Orešković S, et al. Thrombosis following ovarian hyperstimulation syndrome. Gynecol Endocrinol 2014; 30:764.</a></li><li><a class="nounderline abstract_t">Nouri K, Tempfer CB, Lenart C, et al. Predictive factors for recovery time in patients suffering from severe OHSS. Reprod Biol Endocrinol 2014; 12:59.</a></li><li><a class="nounderline abstract_t">Abramov Y, Elchalal U, Schenker JG. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1998; 70:1070.</a></li><li><a class="nounderline abstract_t">Mathur RS, Jenkins JM. Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome? BJOG 2000; 107:943.</a></li><li><a class="nounderline abstract_t">Wiser A, Levron J, Kreizer D, et al. Outcome of pregnancies complicated by severe ovarian hyperstimulation syndrome (OHSS): a follow-up beyond the second trimester. Hum Reprod 2005; 20:910.</a></li></ol></div><div id="topicVersionRevision">Topic 101383 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2660037" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ovarian hyperstimulation syndrome: an update review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10785212" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7929724" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37156263" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37156263" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19007627" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082791" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The diagnosis and management of ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12009355" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292006" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16154051" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608177" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14503971" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27901279" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Dopamine agonists for preventing ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25948367" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Severe ovarian hyperstimulation syndrome complicated by Stenotrophomonas maltophilia peritonitis: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31097257" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ovarian hyperstimulation syndrome: A review for emergency clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31097257" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ovarian hyperstimulation syndrome: A review for emergency clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25014487" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thrombosis following ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24996451" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Predictive factors for recovery time in patients suffering from severe OHSS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848297" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955422" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618246" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outcome of pregnancies complicated by severe ovarian hyperstimulation syndrome (OHSS): a follow-up beyond the second trimester.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
